No-shpa, 40 mg tablets 6 pcs

Name: No-shpa, 40 mg tablets 6 pcs
SKU: 212714
Availability: OutOfStock

€1.00

Out of stock

(E-mail when Stock is available)

EAN: 3582910041870 SKU: 212714 Categories: Medicine, Pain and fever, Pain and spasms

Description

Pharmgroup:

The antispasmodic agent.

Pharmic action:

No-spa is a myotropic antispasmodic, isoquinoline derivative. It has a powerful antispasmodic effect on smooth muscles by inhibiting the enzyme FDE. PDE enzyme is required for hydrolysis of cAMP to AMP. Inhibition of FDE leads to an increase in the concentration of cAMP, which triggers the following cascade reaction: high concentrations of cAMP activate cAMP-dependent phosphorylation of myosin light chain kinase (CLKM).

Phosphorylation of CLSM leads to a decrease in its affinity for the Ca2+-calmodulin complex; as a result, the inactivated form of CLSM maintains muscle relaxation. In addition, cAMP affects the cytosolic concentration of Ca2+ ion by stimulating Ca2+ transport into the extracellular space and the sarcoplasmic reticulum. This lowering of Ca2+-ion concentration by drotaverine through the cAMP explains the antagonistic effect of drotaverine with respect to Ca2+.

In vitro, drotaverine inhibits the FDE4 isoenzyme without inhibiting the FDE3 and FDE5 isoenzymes. Therefore, the effectiveness of drotaverine depends on the concentration of FDE4 in tissues (FDE4 content varies in different tissues). FDE4 is most important for inhibition of contractile activity of smooth muscles, therefore selective inhibition of FDE4 may be useful for treatment of hyperkinetic dyskinesias and various diseases accompanied by spastic state of GIT.

The hydrolysis of CAMP in the myocardium and vascular smooth muscle occurs primarily through the FDE3 isoenzyme, which explains the fact that with high antispasmodic activity, drotaverine has no serious cardiovascular side effects and pronounced effects on the cardiovascular system.
Drotaverine is effective for smooth muscle spasms of both neurogenic and muscular origin. Regardless of the type of autonomic innervation, drotaverine relaxes the smooth muscles of the gastrointestinal tract, biliary tract, genitourinary system.

Indications

Urolithiasis, Pain, Gastrointestinal cramps, Threatened miscarriage, Headache, Enteritis, Gastroduodenitis, Painful menstruation, Renal colic, Gallic colic, Colitis, Gallstone disease, Abdominal bloating, Cholecystitis.ul>

stomach and intestinal spasms

renal colic

painful menstruation

biliary tract dyskinesia, biliary colic, cholecystitis.

Active ingredient

Drotaverine

Composition

Active ingredient:

drotaverine hydrochloride;

Additives:

Magnesium stearate;

Talc;

Povidone;

Corn starch;

Lactose monohydrate;

How to take, the dosage
How to take, the dosage
Ingestion.
The average daily dose is usually 120-240 mg (the daily dose is divided into 2-3 doses).

Interaction
Interaction
Levodopa. When used concomitantly, drotaverine may weaken the anti-Parkinsonian effect of levodopa, i.e., increase stiffness and tremor.
Papaverine, bendazole and other antispasmodics (including m-cholinolytics). Increased antispasmodic action.
Morphine. Reduction of the spasmogenic activity of morphine.
Phenobarbital. Enhancement of the antispasmodic action of drotaverine.
.

Special Instructions
Special Instructions
The use of the drug in case of arterial hypotension requires increased caution.
Each tablet contains 104 mg of lactose.
Lactose can take up to 156 mg (1.5 tablets) when taken, which can cause GI disorders in patients who are lactose intolerant.
The tablets are not appropriate for patients with lactose deficiency, galactosemia, or impaired glucose/galactose absorption syndrome (see Contraindications).
Impact on the ability to drive a car or perform work requiring increased speed of physical and mental reactions.
When taken orally in therapeutic doses, drotaverine has no effect on the ability to drive and perform work requiring increased attention.
If any side effects occur, driving and operating machinery require individual consideration.
In case of dizziness, potentially hazardous activities such as driving and operating machinery should be avoided.

Contraindications
Contraindications
high sensitivity to drotaverine and/or excipients in the drug;
explicit hepatic or renal failure;
Heart failure (reduced cardiac output)
hereditary lactose intolerance, lactose deficiency or lactose syndrome.
Healthy heart failure (decreased cardiac output)
Hereditary lactose intolerance, lactase deficiency, galactosemia or glucose/galactose malabsorption syndrome (due to the presence of lactose in the preparation).
With caution: arterial hypotension.
.

Side effects
Side effects
Systemic system disorders: rarely – palpitations, decreased blood pressure.
CNS disorders: rarely – headache, dizziness, insomnia.
Gastrointestinal disorders: rarely – nausea, constipation.
The immune system: rare – allergic reactions (angioedema, urticaria, rash, itching); unknown frequency – when using the drug it was reported the development of anaphylactic shock with fatal and non-fatal outcome.
.

Overdose
Overdose
Symptoms: cardiac rhythm and conduction disorders, including complete Gis bundle leg block and cardiac arrest, which can be fatal.
Treatment: In cases of overdose, patients should be under medical supervision and, if necessary, they should be given symptomatic and supportive treatment for basic body functions, including induction of vomiting or gastric lavage.

Pregnancy use
Pregnancy use
During pregnancy and lactation can be used when indicated.
It is contraindicated in children under 6 years of age.
.

Similarities
Similarities
No-shpa, Drotaverine, Spasmonet, Drotaverine-Teva

Additional information
Weight 0.015 kg
Shelf life
5 years
Conditions of storage
At temperatures below 30 °C
Manufacturer
Hinoin Pharmaceutical and Chemical Works, Hungary
Medication form
pills
Brand
Hinoin Pharmaceutical and Chemical Works